Alx oncology appoints scott garland to its board of directors

South san francisco, calif., nov. 29, 2022 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced the appointment of scott garland to its board of directors (the “board”) effective november 29, 2022. with more than 30 years of biopharmaceutical industry knowledge, mr. garland brings deep commercial and executive leadership experience.
ALXO Ratings Summary
ALXO Quant Ranking